PT  - JOURNAL ARTICLE
AU  - Hingorani, Mohan
AU  - Dixit, Sanjay
AU  - Pugazhenthi, Pattu
AU  - Hawkyard, Simon
AU  - Robertson, Andrew
AU  - Khafagy, Richard
TI  - Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?—a report of three cases
AID  - 10.7497/j.issn.2095-3941.2014.0025
DP  - 2015 Mar 01
TA  - Cancer Biology and Medicine
PG  - 60--63
VI  - 12
IP  - 1
4099  - http://www.cancerbiomed.org/content/12/1/60.short
4100  - http://www.cancerbiomed.org/content/12/1/60.full
SO  - Cancer Biol Med2015 Mar 01; 12
AB  - Palliative radiotherapy (pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (CRPC). However, evidence that pRT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC progressing after treatment with docetaxel (n=2) and abiraterone (n=1), who responded unusually after pRT for bone pain with the development of a significant biochemical response and restoration of response to systemic therapy. The possibility of pRT influencing metastatic disease in CRPC has not been previously reported, and raises the possibility of radiation-induced modulation of anti-tumor immune response mechanisms that may play a role in the restoration of response to systemic treatment.